FDA dis­cuss­es RWD, RWE with in­dus­try, acad­e­mia

In­dus­try, acad­e­mia and FDA of­fi­cials gath­ered Fri­day in Bethes­da, MD to dis­cuss the use of re­al-world da­ta (RWD) and re­al-world ev­i­dence (RWE) in the pre­mar­ket and post­mar­ket set­tings.

Jacque­line Cor­ri­g­an-Cu­ray, di­rec­tor of CDER’s Of­fice of Med­ical Pol­i­cy, kicked off the joint FDA-Amer­i­can As­so­ci­a­tion for Can­cer Re­search meet­ing to dis­cuss the FDA’s frame­work for us­ing RWE, which was un­veiled in De­cem­ber 2018. The frame­work is meant to guide the FDA on eval­u­at­ing the po­ten­tial use of RWE to sup­port changes to la­bel­ing, in­clud­ing adding or mod­i­fy­ing an in­di­ca­tion or adding com­par­a­tive ef­fec­tive­ness or safe­ty in­for­ma­tion.

“Trans­paren­cy on study de­sign and analy­sis be­fore ex­e­cu­tion is crit­i­cal for en­sur­ing con­fi­dence in the re­sult,” Cor­ri­g­an-Cu­ray said, not­ing that RWE may be able to de­tect long-term but in­fre­quent out­comes.

More re­cent­ly, the FDA is­sued draft guid­ance on the types of RWD and RWE in­for­ma­tion that might be sub­mit­ted. Cor­ri­g­an-Cu­ray al­so of­fered sev­er­al ex­am­ples of when RWE has in­formed ef­fec­tive­ness de­ter­mi­na­tions.

She fur­ther dis­cussed how com­pa­nies should de­cide if da­ta can be con­sid­ered fit for use and how the qual­i­ty of the da­ta can be as­sured by the FDA.

Work on RWE du­pli­ca­tion demon­stra­tion projects is al­so un­der­way, with in­ves­ti­ga­tors from Brigham and Women’s Hos­pi­tal build­ing an ev­i­dence base for re­al world da­ta through large-scale repli­ca­tion of ran­dom­ized con­trolled tri­als. The in­ves­ti­ga­tors said their goal is to un­der­stand for what types of clin­i­cal ques­tions RWD analy­ses can be con­duct­ed with con­fi­dence and how to im­ple­ment such stud­ies.

In ad­di­tion, the FDA is work­ing on a demon­stra­tion project for the FDA’s MyS­tud­ies mo­bile app, de­signed to fa­cil­i­tate the in­put of re­al-world da­ta di­rect­ly by pa­tients which can be linked to elec­tron­ic health da­ta sup­port­ing tra­di­tion­al clin­i­cal tri­als, prag­mat­ic tri­als, ob­ser­va­tion­al stud­ies and reg­istries.

Look­ing for­ward, Cor­ri­g­an-Cu­ray point­ed to ef­forts to in­crease in­ter­nal FDA ed­u­ca­tion on RWE and RWD, con­tin­u­ing to hold pub­lic meet­ings and ob­tain ex­perts’ in­put, and to con­sid­er mech­a­nisms and stan­dards to as­sess RWD qual­i­ty. “We wel­come in­put on ideas re­lat­ed to the reg­u­la­to­ry sci­ence of us­ing this da­ta,” she said, es­pe­cial­ly as the FDA iden­ti­fies ad­di­tion­al guid­ance and eval­u­ates what sit­u­a­tions can re­ly on ob­ser­va­tion­al stud­ies.

Oth­er ses­sions through­out the day dis­cussed pre­mar­ket and post­mar­ket use cas­es, as well as large ge­nom­ic data­bas­es and fu­ture di­rec­tions for RWE.

RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

So­cial im­age: FDA, AP Im­ages


Zachary Brennan

managing editor, RAPS

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

Novartis CEO Vas Narasimhan [via Bloomberg/Getty]

I’m not per­fect: No­var­tis chief Vas Narasimhan al­most apol­o­gizes in the wake of a new cri­sis

Vas Narasimhan has warily stepped up with what might pass as something close to a borderline apology for the latest scandal to engulf Novartis.

But he couldn’t quite get there.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

FDA to Sarep­ta: Your wide­ly an­tic­i­pat­ed fol­lowup to Ex­ondys 51 is not get­ting an ac­cel­er­at­ed OK for Duchenne MD

In one of the least anticipated moves of the year, the FDA has rejected Sarepta’s application for an accelerated approval of its Duchenne MD drug golodirsen after fretting over safety issues.

In a statement that arrived after the bell on Monday, Sarepta explained the CRL, saying:

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

Levi Garraway. Broad Institute via Youtube

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

We found out Monday morning where Levi Garraway was headed after he left Eli Lilly as head of oncology R&D a few days ago. Roche named Garraway as their new chief medical officer, replacing Sandra Horning, who they say is retiring from the company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street analysts that cover Sarepta $SRPT are an upbeat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or offer explanations when an odd setback occurs — as happened recently with a safety signal that was ‘erroneously’ reported last week.

Ritu Baral Cowen
Endpoints News

Basic subscription required

Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: No­var­tis spin­off Nabri­va fi­nal­ly scores its first an­tibi­ot­ic ap­proval

In May, Nabriva Therapeutics suffered a setback after the FDA rejected its antibiotic for complicated urinary tract infections — the Novartis spinoff has now had some better luck with the US agency, which on Monday approved its other drug for community-acquired bacterial pneumonia.

The drug, lefamulin, has been developed as an intravenous and oral formulation and been tested in two late-stage clinical trials. The semi-synthetic compound, whose dosing can be switched between the two formulations, is engineered to inhibit the synthesis of bacterial protein by binding to a part of the bacterial ribosome.

Saqib Islam. CheckRare via YouTube

Spring­Works seeks $115M to push Pfiz­er drugs across fin­ish line while Sat­suma sells mi­graine play in $86M IPO

SpringWorks and Satsuma — both biotech spinouts that have closed B rounds in April — are loading up with IPO cash to boost their respective late-stage plans.

Bain-backed SpringWorks is the better-known company of the two, and it’s gunning for a larger windfall of $115 million to add to $228 million from previous financings. In the process, the Stamford, CT-based team is also drawing the curtains on the partnerships it has in mind for the pair of assets it had initially licensed from Pfizer.

Mi­nor­i­ty racial groups con­tin­ue to be dis­mal­ly rep­re­sent­ed in can­cer tri­als — study

Data reveal that different racial and ethnic groups — by nature and/or nurture — can respond differently in terms of pharmacokinetics, efficacy, or safety to therapeutics, but this disparity is not necessarily accounted for in clinical trials. A fresh analysis of the last decade of US cancer drug approvals suggests the trend continues, cementing previous research that suggests oncology trials are woefully under-representative of the racial makeup of the real world.

Van­da shares slide af­ter FDA spurns their big end­point and re­jects a pitch on jet lag re­lief

Back in the spring of last year, Vanda Pharmaceuticals $VNDA served up a hot stew of mixed data for a slate of endpoints related to what they called clear evidence that their melatonin sleep drug Hetlioz (tasimelteon) could help millions of travelers suffering from jet lag.

Never mind that they couldn’t get a planned 90 people in the study, settling for 25 instead; Vanda CEO Mihael H. Polymeropoulos said they were building on a body of data to prove it would help jet-lagged patients looking for added sleep benefits. And that, they added, would be worth a major upgrade from the agency as they sought to tackle a big market.